Neutralizing monoclonal antibodies for treatment of COVID-19

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Rev Immunol
Main Authors: Taylor, Peter C., Adams, Andrew C., Hufford, Matthew M., de la Torre, Inmaculada, Winthrop, Kevin, Gottlieb, Robert L.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8054133/
https://ncbi.nlm.nih.gov/pubmed/33875867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41577-021-00542-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki